These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31827242)

  • 1. Familial myeloid malignancies with germline TET2 mutation.
    Duployez N; Goursaud L; Fenwarth L; Bories C; Marceau-Renaut A; Boyer T; Fournier E; Nibourel O; Roche-Lestienne C; Huet G; Beauvais D; Berthon C; Cambier N; Quesnel B; Preudhomme C
    Leukemia; 2020 May; 34(5):1450-1453. PubMed ID: 31827242
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
    Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
    Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
    [No Abstract]   [Full Text] [Related]  

  • 4. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation.
    Heller PG; Glembotsky AC; Gandhi MJ; Cummings CL; Pirola CJ; Marta RF; Kornblihtt LI; Drachman JG; Molinas FC
    Blood; 2005 Jun; 105(12):4664-70. PubMed ID: 15741216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
    Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
    Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
    Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.
    Stremenova Spegarova J; Lawless D; Mohamad SMB; Engelhardt KR; Doody G; Shrimpton J; Rensing-Ehl A; Ehl S; Rieux-Laucat F; Cargo C; Griffin H; Mikulasova A; Acres M; Morgan NV; Poulter JA; Sheridan EG; Chetcuti P; O'Riordan S; Anwar R; Carter CR; Przyborski S; Windebank K; Cant AJ; Lako M; Bacon CM; Savic S; Hambleton S
    Blood; 2020 Aug; 136(9):1055-1066. PubMed ID: 32518946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline CEBPA mutations in Korean patients with acute myeloid leukemia.
    Kim HS; Han E; Jang W; Kim M; Kim Y; Han K; Kim HJ; Cho B
    Leuk Res; 2019 Jan; 76():84-86. PubMed ID: 30563700
    [No Abstract]   [Full Text] [Related]  

  • 13. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2 mutation in diffuse large B-cell lymphoma.
    Kubuki Y; Yamaji T; Hidaka T; Kameda T; Shide K; Sekine M; Kamiunten A; Akizuki K; Shimoda H; Tahira Y; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Kitanaka A; Shimoda K
    J Clin Exp Hematop; 2017; 56(3):145-149. PubMed ID: 28331128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
    Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
    Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
    J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.
    Grossmann V; Kohlmann A; Eder C; Haferlach C; Kern W; Cross NC; Haferlach T; Schnittger S
    Leukemia; 2011 May; 25(5):877-9. PubMed ID: 21339759
    [No Abstract]   [Full Text] [Related]  

  • 20. Venetoclax induced complete remission in extramedullary relapse of AML co-harboring
    Pan W; Zhao X; Shi W; Jiang Z; Xiao H
    Leuk Lymphoma; 2020 Nov; 61(11):2756-2759. PubMed ID: 33167720
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.